Cloudbreak Pharma, Inc.

As of December 31, 2025, Cloudbreak Pharma, Inc. carries a market capitalization of 4.39B, placing it among publicly traded companies globally. Its enterprise value stands at 3.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Cloudbreak Pharma, Inc. has 844.57M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Cloudbreak Pharma, Inc. maintains a current ratio of 10.68, meaning it holds 10.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 9, 2026, Cloudbreak Pharma, Inc.'s stock has declined approximately 76.06% over the past 52 weeks. The 50-day moving average sits at 1.23, while the 200-day moving average is 2.44.

As of December 31, 2025, Cloudbreak Pharma, Inc. holds 454.09M in cash and equivalents against 5.93M in total debt, resulting in a net debt position of -308.99M. Total book value stands at 470.72M, with working capital of 453.83M providing operational flexibility.